| Long-term survival | |||
---|---|---|---|---|
Variable | OR | 95% CI | p | |
Gender | 1.16 | 0.64–2.11 | 0.613 | |
Age at metastasis ≤ 65 years (yes versus no) | 2.28 | 1.25–4.15 | 0.007 | |
Right-sided tumor versus other (left-sided and rectum) | 0.52 | 0.26–1.02 | 0.058 | |
Single site metastases versus multiple sites | 1.89 | 1.03–3.48 | 0.039 | |
KRASmutant (exon 2) versus wild-type | 0.74 | 0.41–1.33 | 0.321 | |
First-line therapy | Chemotherapy plus bevacizumab versus other | 2.19 | 1.11–4.33 | 0.024 |
Surgical resection of primary tumor (yes versus no) | 3.18 | 0.93–10.9 | 0.065 | |
Surgical resection of metastasis (yes versus no) | 5.30 | 2.80–10 | < 0.001 | |
Local non-surgical treatment of metastasis (yes versus no) | 4.74 | 0.11–0.27 | < 0.001 | |
Adjuvant treatment (yes versus no) | 1.46 | 0.80–2.69 | 0.217 |